Novavax, Inc. (NASDAQ:NVAX), is a $805 million biotech that develops vaccines for a number of diseases. The stock is currently in a pullback, but this is not surprising because it is happening everywhere in the healthcare sector. But even so, the pullback in Novavax only creates a buying opportunity for long-term outlook investors. Novavax, Inc. (NASDAQ:NVAX), shares after opening at $3.74 moved to $4.06 on last trade day and at the end of the day closed at $4.05. Company price to sales ratio in past twelve months was calculated as 50.70 and price to cash ratio as 5.78. Novavax, Inc. (NASDAQ:NVAX), showed a negative weekly performance of 7.11%.
ImmunoGen, Inc. (NASDAQ:IMGN)’s, shares have been up over a couple of trading sessions following the company’s announcement of encouraging initial results on its oncology candidate, IMGN853, on Apr 8. The stock has gained over 8% since the announcement. ImmunoGen, Inc. (NASDAQ:IMGN), shares advanced 11.02% in last trading session and ended the day on $14.21. ImmunoGen, Inc. (NASDAQ:IMGN), return on equity ratio is recorded as 24.10% and its return on assets is 14.50%. ImmunoGen, Inc. (NASDAQ:IMGN), yearly performance is -4.76%.
On April, 16, 2014, Horizon Pharma Inc (NASDAQ:HZNP), announced that it has received notice of the early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, in connection with its proposed acquisition of Vidara Therapeutics International Ltd. (“Vidara”). The waiting period was scheduled to expire on May 1, 2014. Completion of the transaction remains subject to approval by Horizon’s stockholders and other customary closing conditions. Horizon Pharma Inc (NASDAQ:HZNP), shares moved up 7.24% in last trading session and was closed at $13.18, while trading in range of $ 12.7 – 13.25. Horizon Pharma Inc (NASDAQ:HZNP), year to date (YTD) performance is 72.97%.
Penn Virginia Corporation (NYSE:PVA), an independent oil and gas company, rose to a one-year high of $16 on Tuesday after activist investor Soros Fund Management disclosed that it had taken a 9.18% stake in the company and urged Penn Virginia’s management to consider other strategic alternatives. Penn Virginia Corporation (NYSE:PVA), weekly performance is 0.48%. On last trading day company shares ended up $16.79. Penn Virginia Corporation (NYSE:PVA), distance from 50-day simple moving average (SMA50) is 12.30%. Analysts mean target Price for the company is $19.43.
Leave a Reply